New hope for Hard-to-Treat cancers: first human trial of ISM5939 begins
NCT ID NCT06724042
First seen Jan 06, 2026 · Last updated May 13, 2026 · Updated 18 times
Summary
This early-stage trial tests a new drug, ISM5939, in about 159 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study has three parts: first, finding a safe dose of ISM5939 alone; second, fine-tuning the dose; and third, testing it in combination with other therapies. The main goals are to check safety, side effects, and how the drug behaves in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.